Home Companies Catalysts Deep Dives
Scemblix asciminib APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaOncology
Launch2021-10-29
US LOE2038-10-29
Peak Sales Est$2500M
Formulations[{"id":"scemblix-oral","doses":"20mg, 40mg tablets","route":"Oral","setting":"PATIENT_SELF","frequen
Companies
NVS (ORIGINATOR)100%
Mechanism: BCR-ABL inhibitor (STAMP)
Expert: Specifically targets ABL myristoyl pocket (STAMP) inhibitor of BCR-ABL1
Everyday: Blocks the abnormal protein that causes certain leukemias
Targets: ["BCR-ABL"]
Revenue History
PeriodRevenue ($M)
2024$780M
2025$1,150M
Q4 2024$220M
Q4 2025$320M
Programs (1)
IndicationStageKey StudyRegional Status
Ph+ CML-CPAPPROVEDASCEMBL[{"stage":"APPROVED","region":"US","approval_date":"2021-10"}]
Upcoming Catalysts (1)
Scemblix - 1L CML - FDA Approval H1 2026
Notes
STAMP inhibitor for CML. First-in-class. Replacing older TKIs.
Data from Supabase · Updated 2026-03-24